Evidence map›Paper›PMID 38481218›Full record

ArticleHarm reduction journal2024

Exploring the role of community pharmacies as a harm reduction environment for anabolic-androgenic steroid consumers: triangulating the perspectives of consumers and pharmacists.

Timothy Piatkowski, Sarah Benn, Lkhagvadulam Ayurzana, Michelle King, Sara McMillan, Laetitia Hattingh

Open access · goldAbstract read
In one paragraph

Article in Harm reduction journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Timothy PiatkowskiSchool of Applied Psychology, Griffith University, Gold Coast, QLD, Australia. t.piatkowski@griffith.edu.au.ORCID 0000-0002-6177-0266
Sarah BennSchool of Pharmacy and Medical Sciences, Griffith University, Gold Coast, QLD, Australia.
Lkhagvadulam AyurzanaSchool of Pharmacy and Medical Sciences, Griffith University, Gold Coast, QLD, Australia.
Michelle KingSchool of Pharmacy and Medical Sciences, Griffith University, Gold Coast, QLD, Australia.
Sara McMillanGriffith Centre for Mental Health, Griffith University, Brisbane, QLD, Australia.
Laetitia HattinghSchool of Pharmacy and Medical Sciences, Griffith University, Gold Coast, QLD, Australia.
Griffith University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile community pharmacies have been successful in providing harm reduction support for illicit substance consumers, little research has explored their role in addressing the needs of anabolic-androgenic steroid (AAS) consumers.

objectiveThis study aimed to triangulate the attitudes and experiences of AAS consumers and community pharmacist's regarding AAS harm reduction.

methodsSemi-structured interviews were conducted with AAS consumers (n = 8) and community pharmacists (n = 15) between December 2022 and August 2023 in Australia. Interview data were analysed using reflexive thematic analysis.

resultsWhile consumers emphasised easy access to pharmacies, particularly in urban areas, challenges were noted in rural regions. AAS consumers expressed a preference for community pharmacies, perceiving them as less confronting and a feasible avenue for accessing professional advice, highlighting the potential role of pharmacists in nurturing therapeutic alliances with AAS consumers. Similarly, pharmacists expressed receptivity to providing harm reduction information but acknowledged knowledge gaps, suggesting a need for tailored education programs to support AAS consumers effectively.

conclusionsCommunity pharmacies can be an important environment for AAS harm reduction. Strategies include utilising private spaces for open discussions with AAS consumers and enhancing pharmacists' understanding of AAS to foster trust and support. Further research is needed to address knowledge gaps and training needs for pharmacy staff, with the aim of creating a safer environment for AAS consumers.

Indexed as

Community Pharmacy ServicesPharmaciesAnabolic Androgenic SteroidsHarm ReductionHumansPharmacistsProfessional RoleSteroidsAnabolic Androgenic SteroidsSteroidsAnabolic–androgenic steroidsHarm reductionInjectionsPharmaciesRisk environment

Identifiers

PMID38481218
PMCPMC10935940
OpenAlexW4392752441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.